Skip to main content
Top
Published in: Indian Journal of Pediatrics 2/2018

01-02-2018 | Editorial Commentary

Financial Burden of Treatment of Transfusion Dependent Thalassemia

Author: Deepak Bansal

Published in: Indian Journal of Pediatrics | Issue 2/2018

Login to get access

Excerpt

In view of a lack of a comprehensive nationwide thalassemia control program in the country, children with thalassemia major continue to be born. The birth of a child with thalassemia major is a life changing experience for a family. The medical, financial, and psychosocial burden is enormous and often life-long. Having said that, the life-span and quality of life of a patient with thalassemia is continuing to improve with improved transfusion support, better options for diagnosis of iron-load and chelation, and increasing availability of allogeneic hematopoietic stem cell transplant (HSCT) [13]. However, the optimal treatment for thalassemia is typically deliverable to the small proportion of children hailing from families that are financially empowered and able to access care at the limited thalassemia day care centers in the country. …
Literature
1.
go back to reference Verma IC, Saxena R, Kohli S. Past, present & future scenario of thalassaemic care & control in India. Indian J Med Res. 2011;134:507–21.PubMedPubMedCentral Verma IC, Saxena R, Kohli S. Past, present & future scenario of thalassaemic care & control in India. Indian J Med Res. 2011;134:507–21.PubMedPubMedCentral
2.
go back to reference Mandal S, Sodhi KS, Bansal D, et al. MRI for quantification of liver and cardiac iron in thalassemia major patients: pilot study in Indian population. Indian J Pediatr. 2017;84:276–82.CrossRefPubMed Mandal S, Sodhi KS, Bansal D, et al. MRI for quantification of liver and cardiac iron in thalassemia major patients: pilot study in Indian population. Indian J Pediatr. 2017;84:276–82.CrossRefPubMed
3.
go back to reference Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: a prospective, single center, open-label study. Pediatr Blood Cancer. 2015;62:1592–6.CrossRefPubMed Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: a prospective, single center, open-label study. Pediatr Blood Cancer. 2015;62:1592–6.CrossRefPubMed
5.
go back to reference Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, et al. Economic burden of thalassemia major in Iran, 2015. J Res Health Sci. 2016;16:111–5.PubMed Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, et al. Economic burden of thalassemia major in Iran, 2015. J Res Health Sci. 2016;16:111–5.PubMed
6.
go back to reference Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016;56:1038–45.CrossRefPubMed Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016;56:1038–45.CrossRefPubMed
Metadata
Title
Financial Burden of Treatment of Transfusion Dependent Thalassemia
Author
Deepak Bansal
Publication date
01-02-2018
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 2/2018
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-017-2547-2

Other articles of this Issue 2/2018

Indian Journal of Pediatrics 2/2018 Go to the issue